AKBA
Akebia TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Composite grade D from latest DB weights. Momentum 16.4 / Value 64.9
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.3.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
16
Value
65
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $4.20
Why
Momentum16 · Δ7d -
Value65 · Δ7d +0.3
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
16
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
65
60% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-0.8
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 16.4 / Value 64.9
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$343.37M
Beta
0.38
Shares Out
268.26M
P/E (TTM) · Derived
-61.5
P/S (TTM)
1.78
P/FCF (TTM)
12.45
Rev YoY
-6.6%
EPS YoY
-234.0%
Gross Margin
+80.5%
Op Margin
+7.9%
Net Debt
$29.76M
Current Ratio
1.40
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology